AD
MCID: ALZ034
MIFTS: 87

Alzheimer Disease (AD)

Categories: Cardiovascular diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Alzheimer Disease

MalaCards integrated aliases for Alzheimer Disease:

Name: Alzheimer Disease 58 12 25 54 26 76 38 30 45 39 41
Alzheimer's Disease 39 12 77 26 55 30 6 44 3 15 64 17 74
Presenile and Senile Dementia 58 26 76
Ad 58 26 76
Alzheimer Disease, Late-Onset, Susceptibility to 58 6
Alzheimer Disease, Susceptibility to 58 6
Alzheimer Disease 1, Familial 58 13
Familial Alzheimer Disease 26 74
Alzheimer Disease, Early-Onset, with Cerebral Amyloid Angiopathy 6
Early-Onset Alzheimer Disease with Cerebral Amyloid Angiopathy 76
Primary Senile Degenerative Dementia 26
Autosomal Dominant Alzheimer Disease 76
Dementia Due to Alzheimer's Disease 74
Alzheimer's Disease Pathway Kegg 74
Alzheimer Disease, Late-Onset 58
Alzheimer Disease Type 1 74
Alzheimer-Type Dementia 26
Alzheimers Dementia 12
Alzheimer Disease 1 76
Alzheimer Sclerosis 26
Alzheimer Dementia 26
Alzheimer Syndrome 26
Alzheimers Disease 56
Sdat 26
Ad1 76
Dat 26

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity


HPO:

33
alzheimer disease:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



Summaries for Alzheimer Disease

NINDS : 55 Alzheimer's disease (AD) is an age-related, non-reversible brain disorder that develops over a period of years. Initially, people experience memory loss and confusion, which may be mistaken for the kinds of memory changes that are sometimes associated with normal aging. However, the symptoms of AD gradually lead to behavior and personality changes, a decline in cognitive abilities such as decision-making and language skills, and problems recognizing family and friends. AD ultimately leads to a severe loss of mental function. These losses are related to the worsening breakdown of the connections between certain neurons in the brain and their eventual death. AD is one of a group of disorders called dementias that are characterized by cognitive and behavioral problems. It is the most common cause of dementia among people age 65 and older. There are three major hallmarks in the brain that are associated with the disease processes of AD. Amyloid plaques, which are made up of fragments of a protein called beta-amyloid peptide mixed with a collection of additional proteins, remnants of neurons, and bits and pieces of other nerve cells. Neurofibrillary tangles (NFTs), found inside neurons, are abnormal collections of a protein called tau. Normal tau is required for healthy neurons. However, in AD, tau clumps together. As a result, neurons fail to function normally and eventually die. Loss of connections between neurons responsible for memory and learning. Neurons can't survive when they lose their connections to other neurons. As neurons die throughout the brain, the affected regions begin to atrophy, or shrink. By the final stage of AD, damage is widespread and brain tissue has shrunk significantly.

MalaCards based summary : Alzheimer Disease, also known as alzheimer's disease, is related to alzheimer disease 2 and early-onset, autosomal dominant alzheimer disease, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Alzheimer Disease is APP (Amyloid Beta Precursor Protein), and among its related pathways/superpathways are Alzheimer disease and Presenilin-Mediated Signaling. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include Brain and Blood, and related phenotypes are dementia and parkinsonism

Disease Ontology : 12 A tauopathy that is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability and results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.

Genetics Home Reference : 26 Alzheimer disease is a degenerative disease of the brain that causes dementia, which is a gradual loss of memory, judgment, and ability to function. This disorder usually appears in people older than age 65, but less common forms of the disease appear earlier in adulthood.

NIH Rare Diseases : 54 Alzheimer disease (AD) is a degenerative disease of the brain that causes gradual loss of memory, judgment, and the ability to function socially. Alzheimer disease currently affects about 5 million people. About 75 percent of Alzheimer disease cases are classified as sporadic, which means they occur in people with no history of the disorder in their family. Although the cause of these cases is unknown, genetic changes are likely to play a role. Virtually all sporadic cases of Alzheimer disease begin after age 65, and the risk of developing this condition increases as a person gets older. AD can be subdivided into two groups based on the age of onset: (1) Early-onset (1%-6% of the cases) which start in people younger than 60- 65 years of age (2) Late-onset, which starts in people older than 65 years old. In about 25% of cases, AD is familial (2 or more people in a family have AD). For more information, please visit GARD's familial Alzheimer disease Web page.

OMIM : 58 Alzheimer disease is the most common form of progressive dementia in the elderly. It is a neurodegenerative disorder characterized by the neuropathologic findings of intracellular neurofibrillary tangles (NFT) and extracellular amyloid plaques that accumulate in vulnerable brain regions (Sennvik et al., 2000). Terry and Davies (1980) pointed out that the 'presenile' form, with onset before age 65, is identical to the most common form of late-onset or 'senile' dementia, and suggested the term 'senile dementia of the Alzheimer type' (SDAT). Haines (1991) reviewed the genetics of AD. Selkoe (1996) reviewed the pathophysiology, chromosomal loci, and pathogenetic mechanisms of Alzheimer disease. Theuns and Van Broeckhoven (2000) reviewed the transcriptional regulation of the genes involved in Alzheimer disease. (104300)

MedlinePlus : 44 Alzheimer's disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. AD begins slowly. It first involves the parts of the brain that control thought, memory and language. People with AD may have trouble remembering things that happened recently or names of people they know. A related problem, mild cognitive impairment (MCI), causes more memory problems than normal for people of the same age. Many, but not all, people with MCI will develop AD. In AD, over time, symptoms get worse. People may not recognize family members. They may have trouble speaking, reading or writing. They may forget how to brush their teeth or comb their hair. Later on, they may become anxious or aggressive, or wander away from home. Eventually, they need total care. This can cause great stress for family members who must care for them. AD usually begins after age 60. The risk goes up as you get older. Your risk is also higher if a family member has had the disease. No treatment can stop the disease. However, some drugs may help keep symptoms from getting worse for a limited time. NIH: National Institute on Aging

CDC : 3 Although scientists are learning more every day, right now, they still do not know what causes Alzheimer’s disease.

UniProtKB/Swiss-Prot : 76 Alzheimer disease: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. Alzheimer disease 1: A familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.

PubMed Health : 64 About alzheimer's disease: Alzheimer's disease is the most common cause of dementia. It takes its name from the psychiatrist Alois Alzheimer, who in the early twentieth century was the first person to describe the disease. Over time, people who have Alzheimer’s lose their memory and ability to concentrate. Orientation in space and time become increasingly difficult, and it is also harder for them to manage on their own in everyday life. Those affected need more support as the disease progresses.The course of Alzheimer’s can be positively influenced by a number of different medications and non-drug treatments – but it is not possible to cure the disease or to keep it from progressing. This makes it even more critical for people with Alzheimer’s to receive good care and support: They need loving and stable relationships and a tolerant environment. Many family members need help and assistance too.There are other possible causes of dementia besides Alzheimer’s disease. These include problems with the flow of blood in the brain (vascular dementia). Some people – particularly older people – have both Alzheimer’s and vascular dementia. Medical conditions such as Parkinson’s disease, brain injuries or tumors can also cause dementia. Long-term heavy alcohol consumption may lead to dementia too.There are similarities, but also differences, between the different forms of dementia: The symptoms, the course the disease takes, and the treatment options can all vary. This overview is only about Alzheimer’s.

Wikipedia : 77 Alzheimer''s disease (AD), also referred to simply as Alzheimer''s, is a chronic neurodegenerative... more...

GeneReviews: NBK1161

Related Diseases for Alzheimer Disease

Diseases in the Alzheimer Disease family:

Alzheimer Disease 2 Alzheimer Disease 16
Alzheimer Disease 5 Alzheimer Disease 6
Alzheimer Disease 7 Alzheimer Disease 4
Alzheimer Disease 8 Alzheimer Disease 3
Alzheimer Disease 9 Alzheimer Disease 10
Alzheimer Disease 11 Alzheimer Disease 12
Alzheimer Disease 13 Alzheimer Disease 14
Alzheimer Disease 15 Alzheimer Disease 17
Alzheimer Disease 18 Alzheimer Disease 19
Alzheimer's Disease 1 Early-Onset, Autosomal Dominant Alzheimer Disease

Diseases related to Alzheimer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1184)
# Related Disease Score Top Affiliating Genes
1 alzheimer disease 2 35.4 APP NOS3 PLAU PSEN1
2 early-onset, autosomal dominant alzheimer disease 35.1 APP PSEN1
3 alzheimer disease mitochondrial 34.4 APP MT-ND1
4 amyloidosis 31.5 APP BACE1 PSEN1
5 diabetes mellitus 31.3 CDKN2B-AS1 HFE MIR34A MT-ND1 NOS3
6 disease of mental health 30.9 APP BACE1 PSEN1
7 inclusion body myositis 30.9 APP BACE1 BACE1-AS MIR34A
8 gait apraxia 30.7 APP PSEN1
9 ovarian cancer 30.5 BACE1-AS CDKN2B-AS1 MIR106B MIR146A MIR29A PLAU
10 kluver-bucy syndrome 30.4 APP PSEN1
11 hepatocellular carcinoma 30.2 CDKN2B-AS1 HFE MIR106B MIR107 MIR146A MIR29A
12 leukemia, chronic lymphocytic 2 30.2 MIR106B MIR107 MIR29A MIR34A
13 leukemia, acute myeloid 30.2 CDKN2B-AS1 MIR146A MIR328 MPO
14 thyroid cancer, nonmedullary, 1 30.0 MIR146A MIR29A MIR34A
15 colorectal cancer 29.7 BACE1-AS CDKN2B-AS1 MIR106B MIR107 MIR29A MIR328
16 oral squamous cell carcinoma 29.7 MIR107 MIR146A MIR29A MIR34A
17 alzheimer disease 3 12.7
18 alzheimer disease 6 12.6
19 alzheimer disease 4 12.6
20 alzheimer disease 19 12.6
21 alzheimer disease 9 12.6
22 alzheimer disease 18 12.5
23 alzheimer disease 5 12.4
24 alzheimer disease 8 12.4
25 alzheimer disease 12 12.4
26 alzheimer disease 7 12.3
27 alzheimer disease 10 12.3
28 alzheimer disease 11 12.3
29 alzheimer disease 14 12.3
30 alzheimer disease 13 12.3
31 alzheimer disease 15 12.3
32 alzheimer disease 17 12.2
33 alzheimer disease 16 12.1
34 alzheimer disease without neurofibrillary tangles 12.1
35 alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology 12.1
36 hyper-ige recurrent infection syndrome 1, autosomal dominant 11.9
37 dementia, lewy body 11.9
38 immunodeficiency 27b 11.8
39 alzheimer's disease 1 11.7
40 myopathy, centronuclear, 1 11.7
41 renal tubular acidosis, distal, autosomal dominant 11.7
42 hypocalcemia, autosomal dominant 1 11.6
43 supranuclear palsy, progressive, 1 11.5
44 posterior cortical atrophy 11.4
45 parkinson disease, late-onset 11.4
46 down syndrome 11.4
47 schizophrenia 11.3
48 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 11.3
49 cerebral amyloid angiopathy, app-related 11.3
50 dementia - subcortical 11.3

Comorbidity relations with Alzheimer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 55)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Amnestic Disorder Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Communicating Hydrocephalus Conduct Disorder
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dental Caries
Dermatomycosis Encephalopathy
Fecal Incontinence Folic Acid Deficiency Anemia
Generalized Atherosclerosis Grn-Related Frontotemporal Dementia
Heart Disease Hypoglycemia
Hypothyroidism Intermittent Explosive Disorder
Intestinal Volvulus Iron Deficiency Anemia
Kidney Disease Kohlschutter-Tonz Syndrome
Latent Syphilis Major Depressive Disorder
Marasmus Neurogenic Bladder
Nutritional Deficiency Disease Obstructive Hydrocephalus
Ocular Motor Apraxia Oral Candidiasis
Osteoporosis Paralytic Ileus
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Pernicious Anemia Personality Disorder
Protein-Energy Malnutrition Pyelonephritis
Scabies Schizophrenia

Graphical network of the top 20 diseases related to Alzheimer Disease:



Diseases related to Alzheimer Disease

Symptoms & Phenotypes for Alzheimer Disease

Human phenotypes related to Alzheimer Disease:

33 (show all 7)
# Description HPO Frequency HPO Source Accession
1 dementia 33 HP:0000726
2 parkinsonism 33 HP:0001300
3 neurofibrillary tangles 33 HP:0002185
4 senile plaques 33 HP:0100256
5 alzheimer disease 33 HP:0002511
6 long-tract signs 33 HP:0002423
7 decreased level of gaba in serum 33 HP:0410054

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
parkinsonism
presenile and senile dementia
long tract signs
neurofibrillary tangles composed of disordered microtubules

Clinical features from OMIM:

104300

UMLS symptoms related to Alzheimer Disease:


seizures, tremor, angina pectoris, myoclonus, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness

Drugs & Therapeutics for Alzheimer Disease

PubMedHealth treatment related to Alzheimer Disease: 64

People who have Alzheimer’s need long-term help and treatment. Depending on their needs, their life situation and the stage of disease, a whole team of people may be involved in providing care. These could include trained doctors, psychologists, nurses and social workers, as well as volunteers. Both treatment with medications and non-drug interventions aim toincrease quality of life,keep the ability to do everyday tasks and stay independent for as long as possible,reduce mental health problems, andhelp family members to cope better.The most common medications used to treat Alzheimer’s disease include cholinesterase inhibitors, memantine and extracts from the leaves of the Ginkgo biloba tree.Examples of non-drug treatments include memory and orientation training, doing everyday activities as a group, or art therapy, aromatherapy, and animal-assisted or music therapy. Physical activities and massages can help too. Caregiver training for family members is important too.

Drugs for Alzheimer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 739)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 19982-08-2 4054
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
4
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
5
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120014-06-4 3152
6
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 357-70-0 9651
7
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Not Applicable 68-04-2
8
Acetylcarnitine Approved, Investigational Phase 4,Phase 2 3040-38-8 7045767
9
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106266-06-2 5073
10
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123441-03-2 77991
11
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
12
Levodopa Approved Phase 4,Phase 1,Phase 2,Not Applicable 59-92-7 6047
13
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
14
Clopidogrel Approved Phase 4,Phase 3,Not Applicable 120202-66-6, 113665-84-2 60606
15
Warfarin Approved Phase 4,Phase 3,Phase 1 81-81-2 54678486 6691
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 50-78-2 2244
17
Rivaroxaban Approved Phase 4 366789-02-8
18
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
19
Huperzine A Approved, Experimental Phase 4,Phase 2,Phase 3 102518-79-6
20
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
21
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
22
Atorvastatin Approved Phase 4,Phase 3,Phase 2 134523-00-5 60823
23
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
24
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
25
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 71-58-9
26
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
27
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
28
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 89594 942
29
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
30
Lithium carbonate Approved Phase 4,Phase 2,Phase 1,Not Applicable 554-13-2
31
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 15589840 11953898
32
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 13422-55-4
33
Isoflurane Approved, Vet_approved Phase 4,Phase 1,Not Applicable 26675-46-7 3763
34
Carvedilol Approved, Investigational Phase 4,Phase 2 72956-09-3 2585
35
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
36
Sodium oxybate Approved Phase 4 502-85-2 5360545
37
Quinidine Approved, Investigational Phase 4,Phase 3,Phase 2 56-54-2 441074
38
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
39
Dextromethorphan Approved Phase 4,Phase 3,Phase 2,Phase 1 125-71-3 5362449 5360696
40
Dextroamphetamine Approved, Illicit Phase 4,Phase 3 51-64-9 5826
41
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113-45-1 4158
42
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
43
Cilostazol Approved, Investigational Phase 4,Phase 2,Phase 3 73963-72-1 2754
44
Ramipril Approved Phase 4 87333-19-5 5362129
45
Valproic Acid Approved, Investigational Phase 4,Phase 3,Early Phase 1 99-66-1 3121
46
Sertraline Approved Phase 4,Phase 2,Phase 3,Not Applicable 79617-96-2 68617
47
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
48
Pravastatin Approved Phase 4 81093-37-0 54687
49
Amisulpride Approved, Investigational Phase 4,Phase 1 71675-85-9, 53583-79-2 2159
50
Norepinephrine Approved Phase 4,Phase 1,Not Applicable 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 2728)
# Name Status NCT ID Phase Drugs
1 Memantine Treatment in Alzheimer's Disease Patients Unknown status NCT03168997 Phase 4 Memantine Hydrochloride
2 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
3 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4 Galantamine (Reminyl®);Placebo/Galantamine (Reminyl®)
4 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
5 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
6 A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease Unknown status NCT03151382 Phase 4 Tandospirone Citrate;Donepezil Hydrochloride
7 Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease Unknown status NCT02955706 Phase 4 Acetyl-L-Carnitine;Placebo of Acetyl-L-Carnitine
8 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
9 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
10 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
11 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
12 A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients Unknown status NCT02648906 Phase 4 Choline alfoscerate;Placebo
13 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4 Levodopa
14 Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients Unknown status NCT00842920 Phase 4 Simvastatin;Placebo
15 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
16 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
17 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
18 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
19 Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass Unknown status NCT00297245 Phase 4 cognitive function
20 Memantine for Post-Operative Pain Control Unknown status NCT01041313 Phase 4 Memantine;Placebo
21 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
22 Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study Unknown status NCT02190019 Phase 4
23 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
24 Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) Withdrawn NCT01822951 Phase 4 Cerebrolysin;Donepezil
25 Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors Completed NCT01529619 Phase 4 Rivastigmine transdermal patch
26 Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care Active, not recruiting NCT01993836 Phase 4 Total intravenous anesthesia with propofol;General anesthesia with isoflurane
27 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients Completed NCT01948791 Phase 4 ENA713
28 NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients. Completed NCT02703636 Phase 4 Rivastigmine Patch
29 Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease Recruiting NCT03703856 Phase 4 Memantine;Placebo
30 Trial of Carvedilol in Alzheimer's Disease Completed NCT01354444 Phase 4 Carvedilol;Placebo
31 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed NCT00381381 Phase 4 Donepezil
32 Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease Completed NCT02097056 Phase 4 Donepezil HCL
33 Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. Completed NCT00731224 Phase 4 Rivastigmine transdermal patch
34 The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease Completed NCT01054976 Phase 4 Galantamine
35 Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease Completed NCT02787746 Phase 4 Donepezil
36 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4 Rivastigmine 4.6 mg/24 h (5 cm^2);Rivastigmine 9.5 mg/24 h (10 cm^2);Rivastigmine 13.3 mg/24 h (15 cm^2);Placebo
37 Escitalopram for the Treatment of Depression in Alzheimer's Disease Completed NCT01841125 Phase 4 escitalopram;Placebo
38 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed NCT00120874 Phase 4 Memantine
39 Double Blind Study of Trp01 in Patients With Alzheimer's Disease Completed NCT00202124 Phase 4 Tryptophan
40 Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease Completed NCT00476008 Phase 4 Memantine;Placebo
41 Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease Completed NCT00561392 Phase 4 Rivastigmine 5 and 10 cm^2 patch
42 Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease Not yet recruiting NCT03821857 Phase 4
43 Neural Correlates In Mild Alzheimer's Disease Completed NCT00477659 Phase 4 donepezil HCl (Aricept)
44 A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease Completed NCT01047579 Phase 4 Rivastigmine transdermal
45 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed NCT00551161 Phase 4 memantine
46 A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease Completed NCT00035204 Phase 4 galantamine
47 Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients Terminated NCT00369603 Phase 4 Razadyne ER;Aricept
48 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Recruiting NCT03082755 Phase 4 Gabapentin Enacarbil;Placebo Oral Tablet
49 Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease Withdrawn NCT00711204 Phase 4 Donepezil Hydrochloride (Aricept)
50 Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease Completed NCT00469456 Phase 4 Memantine;placebo

Search NIH Clinical Center for Alzheimer Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alzheimer Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alzheimer Disease:
NEUROSTEM-AD, human mesenchymal stem cells for the treatment of Alzheimer's disease
Embryonic/Adult Cultured Cells Related to Alzheimer Disease:
Umbilical cord blood-derived mesenchymal stem/progenitor cells PMIDs: 23293711 22015609

Cochrane evidence based reviews: alzheimer disease

Genetic Tests for Alzheimer Disease

Genetic tests related to Alzheimer Disease:

# Genetic test Affiliating Genes
1 Alzheimer's Disease 30 A2M APP HFE MPO NOS3 PLAU
2 Alzheimer Disease 30

Anatomical Context for Alzheimer Disease

MalaCards organs/tissues related to Alzheimer Disease:

42
Brain, Testes, Cortex, Heart, Eye, Endothelial, Temporal Lobe
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alzheimer Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Brain Forebrain White Matter Fibrous Astrocyte Cells Affected by disease, potential therapeutic candidate
2 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
3 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
4 Brain Neocortex Protoplasmic Astrocyte Cells Affected by disease, potential therapeutic candidate
5 Brain Hippocampus Affected by disease

Publications for Alzheimer Disease

Articles related to Alzheimer Disease:

(show top 50) (show all 20391)
# Title Authors Year
1
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease. ( 29920980 )
2019
2
Deficient neurotrophic factors of CSPG4-type neural cell exosomes in Alzheimer disease. ( 29924942 )
2019
3
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. ( 29855563 )
2019
4
In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. ( 29777006 )
2019
5
Alzheimer disease detection from structural MR images using FCM based weighted probabilistic neural network. ( 29460167 )
2019
6
Systems Delivery Innovation for Alzheimer Disease. ( 30477913 )
2019
7
Efficacy of Cognitive Rehabilitation in Alzheimer Disease: A 1-Year Follow-Up Study. ( 30477375 )
2019
8
Memantine: From Alzheimer Disease to Traumatic Brain Injury. ( 30471450 )
2019
9
Instance-Based Representation Using Multiple Kernel Learning for Predicting Conversion to Alzheimer Disease. ( 30415632 )
2019
10
A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18F-FDG PET of the Brain. ( 30398430 )
2019
11
Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. ( 30382303 )
2019
12
Risk Factors of Behavioral and Psychological Symptoms in Patients with Alzheimer Disease: The Clinical Research of Dementia of South Korea Study. ( 30369216 )
2019
13
Resting-State Functional Connectivity in Subjective Cognitive Impairment: Impairment prior to Alzheimer Disease. ( 30351252 )
2019
14
The Possibility of an Infectious Etiology of Alzheimer Disease. ( 30338482 )
2019
15
The Residual Center of Mass: An Image Descriptor for the Diagnosis of Alzheimer Disease. ( 30328551 )
2019
16
Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study. ( 30325873 )
2019
17
Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy. ( 30191975 )
2019
18
The Effect of Changing the Amyloid β42 Cut-off of Cerebrospinal Fluid Biomarkers on Alzheimer Disease Diagnosis in a Memory Clinic Population in Norway. ( 30106756 )
2019
19
Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. ( 30052328 )
2019
20
Intrahippocampal Transplantation of Undifferentiated Human Chorionic- Derived Mesenchymal Stem Cells Does Not Improve Learning and Memory in the Rat Model of Sporadic Alzheimer Disease. ( 30033876 )
2019
21
ERα Gene Promoter Methylation in Cognitive Function and Quality of Life of Patients With Alzheimer Disease. ( 30947592 )
2019
22
Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. ( 30944239 )
2019
23
A call for a global 'bigger' data approach to Alzheimer disease. ( 30940921 )
2019
24
Therapeutic Role of Transcranial Direct Current Stimulation in Alzheimer Disease Patients: Double-Blind, Placebo-Controlled Clinical Trial. ( 30940012 )
2019
25
Studies Further Support Transmissibility of Alzheimer Disease-Associated Proteins. ( 30938780 )
2019
26
Turning up mitophagy in Alzheimer disease. ( 30936509 )
2019
27
An Experimental Ketogenic Diet for Alzheimer Disease Was Nutritionally Dense and Rich in Vegetables and Avocado. ( 30931426 )
2019
28
The sociodemographic characteristics and dietary and blood plasma fatty acid profiles of elderly Saudi women with Alzheimer disease. ( 30927917 )
2019
29
Association of Rare Coding Mutations With Alzheimer Disease and Other Dementias Among Adults of European Ancestry. ( 30924900 )
2019
30
Association of Neuropathologically Confirmed Frontotemporal Dementia and Alzheimer Disease With Criminal and Socially Inappropriate Behavior in a Swedish Cohort. ( 30924889 )
2019
31
Mitophagy and NAD+ inhibit Alzheimer disease. ( 30922179 )
2019
32
Microbes and Alzheimer' disease: lessons from H. pylori and GUT microbiota. ( 30915725 )
2019
33
Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. ( 30913958 )
2019
34
SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. ( 30911827 )
2019
35
The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment. ( 30910421 )
2019
36
Strategies for the Recruitment and Retention of Racial/Ethnic Minorities in Alzheimer Disease and Dementia Clinical Research. ( 30907319 )
2019
37
Resolving atherosclerosis and Alzheimer disease. ( 30903022 )
2019
38
Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. ( 30898012 )
2019
39
Alzheimer disease mice improve with CRISPR-Cas9 gene editing. ( 30894699 )
2019
40
Comment on: Serum Cholesterol and Incident Alzheimer Disease: Findings From the Adult Changes in Thought Study. ( 30893464 )
2019
41
PSEN2 (presenilin 2) mutants linked to familial Alzheimer disease impair autophagy by altering Ca2+ homeostasis. ( 30892128 )
2019
42
Donepezil's Effects on Brain Functions of Patients With Alzheimer Disease: A Regional Homogeneity Study Based on Resting-State Functional Magnetic Resonance Imaging. ( 30875345 )
2019
43
Relative risk for Alzheimer disease based on complete family history. ( 30867271 )
2019
44
Longevity gene KLOTHO may play a role in Alzheimer disease. ( 30867268 )
2019
45
Deep convolutional neural networks for segmenting 3D in vivo multiphoton images of vasculature in Alzheimer disease mouse models. ( 30865678 )
2019
46
Genomic variation in educational attainment modifies Alzheimer disease risk. ( 30863791 )
2019
47
Correction: Genetic risk for schizophrenia and psychosis in Alzheimer disease. ( 30862939 )
2019
48
Comparative analysis of methods of volume adjustment in hippocampal volumetry for the diagnosis of Alzheimer disease. ( 30857897 )
2019
49
Preclinical Alzheimer Disease and the Dawn of the Pre-Caregiver. ( 30855658 )
2019
50
Why Amyloid Is Still a Target for Alzheimer disease Clinical Trials. ( 30851119 )
2019